Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
Am J Transplant. 2010 Sep;10(9):2008-16. doi: 10.1111/j.1600-6143.2010.03213.x. Epub 2010 Jul 20.
Numerous studies report a strong association between pretransplant end-stage renal disease (ESRD) duration and diminished transplant outcomes. However, cumulative waiting time may reflect distinct phases and processes related to patients' physiological condition as well as pre-existing morbidity and access to care. The relative impact of pre- and postlisting ESRD durations on transplant outcomes is unknown. We examined the impact of these intervals from a national cohort of kidney transplant recipients from 1999 to 2008 (n = 112,249). Primary factors explaining prelisting ESRD duration were insurance and race, while primary factors explaining postlisting ESRD duration were blood type, PRA% and variation between centers. Extended time from ESRD to waitlisting had significant dose-response association with overall graft loss (AHR = 1.26 for deceased donors [DD], AHR = 1.32 for living donors [LD], p values < 0.001). Contrarily, time from waitlisting (after ESRD) to transplantation had negligible effects (p = 0.10[DD], p = 0.57[LD]). There were significant associations between pre- and postlisting ESRD time with posttransplant patient survival, however prelisting time had over sixfold greater effect. Prelisting ESRD time predominately explains the association of waiting time with transplant outcomes suggesting that factors associated with this interval should be prioritized for interventions and allocation policy. The degree to which the effect of prelisting ESRD time is a proxy for comorbid conditions, socioeconomic status or access to care requires further study.
许多研究报告称,移植前终末期肾病(ESRD)持续时间与移植结果降低之间存在很强的关联。然而,累计等待时间可能反映了与患者生理状况以及预先存在的发病率和获得护理机会相关的不同阶段和过程。预先和列入名单后的 ESRD 持续时间对移植结果的相对影响尚不清楚。我们从 1999 年至 2008 年的全国肾脏移植受者队列中研究了这些时间间隔的影响(n=112249)。解释列入名单前 ESRD 持续时间的主要因素是保险和种族,而解释列入名单后 ESRD 持续时间的主要因素是血型、PRA%和中心之间的差异。从 ESRD 到列入名单的时间延长与整体移植物丢失呈显著剂量反应关系(对于已故供体,AHR=1.26;对于活体供体,AHR=1.32,p 值<0.001)。相反,从列入名单(ESRD 后)到移植的时间几乎没有影响(p=0.10[已故供体],p=0.57[活体供体])。预先和列入名单后的 ESRD 时间与移植后患者存活率之间存在显著关联,但预先列入名单的时间的影响是后者的六倍以上。列入名单前的 ESRD 时间主要解释了等待时间与移植结果之间的关联,这表明应优先考虑与该时间段相关的因素进行干预和分配政策。预先列入名单的 ESRD 时间的影响在多大程度上是合并症、社会经济地位或获得护理机会的代理,需要进一步研究。